Bio-Rad Laboratories (BIO) was Initiated by CL King to “Buy”. CL King advised their investors in a research report released on Oct 13, 2016.
On the company’s financial health, Bio-Rad Laboratories reported $0.61 EPS for the quarter, missing the analyst consensus estimate by $ -0.52 based on the information available during the earnings call on Aug 3, 2016. Analyst had a consensus of $1.13. The company had revenue of $516.78 million for the quarter, compared to analysts expectations of $497.80 million. The company’s revenue was up 2.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.97 EPS.
Bio-Rad Laboratories closed down -2.67 points or -1.62% at $161.77 with 2,07,483 shares getting traded on Tuesday. Post opening the session at $163.51, the shares hit an intraday low of $160.482 and an intraday high of $163.84 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Sep 14, 2016, James R Stark (VP, Corporate Controller) sold 76 shares at $158.09 per share price. According to the SEC, on Sep 14, 2016, Giovanni Magni (EVP, Chief Strategy Officer) sold 92 shares at $158.07 per share price. On Sep 14, 2016, John Hertia (Executive Vice President) sold 228 shares at $158.08 per share price, according to the Form-4 filing with the securities and exchange commission.
Bio-Rad Laboratories Inc. (Bio-Rad) manufactures and supplies products and systems used for the life science research healthcare analytical chemistry and other markets. The Company offers products to separate complex chemical and biological materials and to identify analyze and purify their components. Bio-Rad operates in two segments: Life Science and Clinical Diagnostics. The Companys Life Science segment develops manufactures and markets a range of over 5000 reagents apparatus and laboratory instruments. The Companys Clinical Diagnostics segment designs manufactures sells and supports test systems informatics systems test kits and quality controls that serve clinical laboratories in the global diagnostics market. Bio-Rads product brands include Droplet Digital and BioPlex. As of December 31 2014 the Company had direct distribution channels in over 35 countries outside the United States through subsidiaries.